Open house drug discount agreements Eptinezumab

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 03, 2028 · 553 days left·Open·Supplies·Framework

Structured notice only

Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Eptinezumab, ATC N02CD05

50/100

Opportunity Score

Needs reviewLow complexity

SuppliesFrameworkOpen

Why this score?

Opportunity

50 / 100

Complexity

20 / 100

Risk factors

This open house model is explicitly not subject to public procurement law. Legal recourse differs (social courts instea...

No indication of volumes or expected revenue – financial risk without guaranteed sales.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

Description
Industries & Services
Capabilities
Market & Experience
Certifications

Overview

Moderate opportunity

Key Facts

Framework procurement
Supplies contract
1 lot
Duration until Apr 2028
Non-exclusive discount agreements for the pharmaceutical product Eptinezumab (ATC N02CD05).
Open house model – no competitive selection, all eligible companies can join.

Show full summary

Open house (non-procurement law) for non-exclusive discount agreements on the active ingredient Eptinezumab (ATC N02CD05) with AOK Bayern. Contracts can be concluded at any time until 03.03.2028, with earliest start on 01.05.2026 and end on 30.04.2028. All interested pharmaceutical companies meeting the eligibility criteria can participate; no selection occurs.

Risks

This open house model is explicitly not subject to public procurement law. Legal recourse differs (social courts instea...

No indication of volumes or expected revenue – financial risk without guaranteed sales.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

Must be a pharmaceutical company (pharmazeutisches Unternehmen).
Provide signed contract and signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Administrative

Submit signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).

Requirements may be incomplete.

Award Criteria

Lot 1

No award criteria (open house model).

Buyer

Name

AOK Bayern - Die Gesundheitskasse

Location

München, DEU

[email protected]

Website

www.aok.de

Buyer profile

Open profile

Identifier

DE811695320

Activity

Health

Lots (1)

LOT-0001

Open house drug discount agreements Eptinezumab

Non-exclusive discount agreements for Eptinezumab (ATC N02CD05). Contracts run with all eligible pharmaceutical companies. Monthly cutoff for contract start is the 3rd of each month.

SuppliesFrameworkEU fundedElectronic submission

Location

DE212, Germany

Duration

Apr 2026 - Apr 2028

Procurement Details

Publication date: 15 Mar 2026
Languages: German

Reference metadata

Legal basis: 32014L0024

Reference IDs

Tender ID: 178615-2026

Documents (2)

Procurement document 1 Submission portal 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3